PSMD4 and hepatocellular carcinoma: Moreover, the patients with low MCB1 expression displayed longer survival time following sorafenib treatment after HCC relapse, while patients with high MCB1 levels exhibited no response to sorafenib therapy (Figure 4B; Figure S6B, Supporting Information).